Acumen Q2 FY26 net loss narrows to $32.7 million; R&D expenses fall to $27.8 million
ABOS•Pipeline updates and timelines
ALTITUDE-AD Phase 2 topline results for sabirnetug in early Alzheimer's disease are expected in late 2026.
Two Enhanced Brain Delivery candidates were nominated; the lead program IND filing is targeted for mid-2027.
Cash position declines from prior quarter
Cash, cash equivalents and marketable securities dropped to $110.2 million at June 30 from $128.4 million at March 31.
Quarterly loss and operating expenses improve
Acumen posted a net loss of $32.7 million, narrowing from $41 million a year earlier.
Operating loss improved to $32.6 million from $41.8 million, as research and development expenses fell to $27.8 million from $37.1 million.
